NasdaqGS:ARQTBiotechs
Arcutis Biotherapeutics (ARQT) Q4 Profitability Raises Questions For Bullish Growth Narrative
Arcutis Biotherapeutics (ARQT) has just posted higher top and bottom line figures for FY 2025, with Q4 revenue of US$129.5 million and basic EPS of US$0.14, alongside net income of US$17.4 million. The company’s quarterly revenue moved from US$44.8 million in Q3 2024 to US$65.8 million in Q1 2025 and then to US$99.2 million and US$129.5 million in Q3 and Q4 2025. Basic EPS shifted from a loss of US$0.33 in Q3 2024 to a profit of US$0.06 in Q3 2025 and US$0.14 in Q4 2025, putting improving...